Evid Invest
Holders — by stockHoldings — by fund

RA CAPITAL MANAGEMENT, L.P.

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001346824

$11.51B

disclosed book value

84

positions

23.8%

largest position share

Positions, as of 2026-06-30

top 84 of 84 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1ASCENDIS PHARMA A/S10.3M$2.74B23.8%
2PBLSPARABILIS MEDICINES INC28.9M$791.9M6.9%
3RYTMRHYTHM PHARMACEUTICALS INC6.7M$740.2M6.4%
4PCVXVAXCYTE INC11.5M$667.0M5.8%
5SIONSIONNA THERAPEUTICS INC9.9M$435.7M3.8%
6TYRATYRA BIOSCIENCES INC12.2M$389.6M3.4%
7EWTXEDGEWISE THERAPEUTICS INC8.4M$341.0M3%
8NEWAMSTERDAM PHARMA CO NV9.6M$323.7M2.8%
9COAGHEMAB THERAPEUTICS HOLDINGS7.8M$286.8M2.5%
10SEPNSEPTERNA INC7.0M$234.3M2%
11BCAXBICARA THERAPEUTICS INC7.3M$215.4M1.9%
12MLYSMINERALYS THERAPEUTICS INC7.7M$207.6M1.8%
13GH RESEARCH PLC7.6M$205.3M1.8%
14IRONDISC MEDICINE INC2.5M$179.2M1.6%
15SGPSPYGLASS PHARMA INC8.0M$178.6M1.6%
16ARTVARTIVA BIOTHERAPEUTICS INC18.0M$174.2M1.5%
17JANXJANUX THERAPEUTICS INC11.2M$171.9M1.5%
18TSHATAYSHA GENE THERAPIES INC23.6M$160.4M1.4%
19BCRXBIOCRYST PHARMACEUTICALS INC15.8M$158.3M1.4%
20WAVE LIFE SCIENCES LTD27.0M$156.7M1.4%
21NUVALENT INC-A1.2M$153.9M1.3%
22ABVXABIVAX SA-ADR1.1M$150.9M1.3%
23ORKAORUKA THERAPEUTICS INC1.6M$148.0M1.3%
24CLYMCLIMB BIO INC11.3M$147.4M1.3%
25SLDBSOLID BIOSCIENCES INC12.0M$120.2M1%
26ZLABZAI LAB LTD-ADR5.7M$109.1M0.9%
27SPRYARS PHARMACEUTICALS INC10.9M$87.0M0.8%
28XNCRXENCOR INC5.3M$84.9M0.7%
29JBIOJADE BIOSCIENCES INC3.7M$81.6M0.7%
30NTLAINTELLIA THERAPEUTICS INC4.5M$76.6M0.7%
31LBRXLB PHARMACEUTICALS INC2.2M$71.7M0.6%
32DFTXDEFINIUM THERAPEUTICS INC1.5M$70.6M0.6%
33ACRSACLARIS THERAPEUTICS INC12.7M$67.3M0.6%
34FDMT4D MOLECULAR THERAPEUTICS IN5.0M$67.2M0.6%
35SANASANA BIOTECHNOLOGY INC18.8M$65.4M0.6%
36DAMORA THERAPEUTICS INC2.4M$62.4M0.5%
37MNPRMONOPAR THERAPEUTICS INC667,207$61.8M0.5%
38ABOSACUMEN PHARMACEUTICALS INC21.0M$56.1M0.5%
39GERNGERON CORP42.8M$54.8M0.5%
40RZLTREZOLUTE INC9.4M$49.1M0.4%
41EVMNEVOMMUNE INC3.5M$46.4M0.4%
42VORVOR BIOPHARMA INC2.4M$44.2M0.4%
43IPSCCENTURY THERAPEUTICS INC17.8M$43.5M0.4%
44AKTSAKTIS ONCOLOGY INC1.3M$42.4M0.4%
45BIOABIOAGE LABS INC1.7M$41.0M0.4%
46CCCCC4 THERAPEUTICS INC8.0M$37.4M0.3%
47MIRMMIRUM PHARMACEUTICALS INC318,554$37.3M0.3%
48CAPRCAPRICOR THERAPEUTICS INC1.5M$36.3M0.3%
49PEPGPEPGEN INC20.1M$36.1M0.3%
50PRLDPRELUDE THERAPEUTICS INC6.5M$34.5M0.3%
51NKTXNKARTA INC10.8M$30.6M0.3%
52QTTBQ32 BIO INC2.3M$29.7M0.3%
53AVRANTERIS TECHNOLOGIES GLOBAL3.0M$29.6M0.3%
54EDITEDITAS MEDICINE INC8.9M$28.8M0.3%
55OVIDOVID THERAPEUTICS INC10.5M$28.2M0.2%
56ASMBASSEMBLY BIOSCIENCES INC1.0M$28.0M0.2%
57ALXOALX ONCOLOGY HOLDINGS INC13.0M$26.9M0.2%
58BNTCBENITEC BIOPHARMA INC1.9M$24.8M0.2%
59LENZLENZ THERAPEUTICS INC4.2M$23.7M0.2%
60LXEOLEXEO THERAPEUTICS INC5.0M$23.3M0.2%
61ACRVACRIVON THERAPEUTICS INC12.2M$21.8M0.2%
62ALTALTIMMUNE INC6.5M$19.8M0.2%
63KPTIKARYOPHARM THERAPEUTICS INC1.9M$18.7M0.2%
64DRUGBRIGHT MINDS BIOSCIENCES INC265,000$18.6M0.2%
65AVTXAVALO THERAPEUTICS INC1.0M$18.5M0.2%
66OKURONKURE THERAPEUTICS INC-A4.0M$18.2M0.2%
67FTHFAETH THERAPEUTICS INC722,020$18.1M0.2%
68AURAAURA BIOSCIENCES INC2.5M$17.8M0.2%
69SABSSAB BIOTHERAPEUTICS INC4.4M$17.2M0.1%
70SPTXSEAPORT THERAPEUTICS INC700,000$15.2M0.1%
71PALIPALISADE BIO INC7.1M$14.9M0.1%
72HELIX ACQUISITION CORP-CL A1.3M$13.3M0.1%
73WAYWAYSTAR HOLDING CORP529,400$10.9M0.1%
74EQEQUILLIUM INC3.1M$9.9M0.1%
75MGNXMACROGENICS INC1.9M$8.6M0.1%
76PERCEPTIVE CAPITAL SOLUTIONS750,000$8.2M0.1%
77ACETADICET BIO INC932,624$8.1M0.1%
78NEWAMSTERDAM PHARMA CO NV-27333,333$7.1M0.1%
79CRVSCORVUS PHARMACEUTICALS INC450,000$6.7M0.1%
80RANIRANI THERAPEUTICS HOLDINGS-A8.5M$6.5M0.1%
81JATT II ACQUISITION CORP500,000$5.7M0%
82AMANAT ACQUISITION CORP CL A375,000$3.8M0%
83HOWLWEREWOLF THERAPEUTICS INC2.4M$859,3490%
84PTNPALATIN TECHNOLOGIES INC62,124$670,3180%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.